Analysis of Roch Holding AG - wave analysisExpecting fall in share price until 2026 = good moment to buy
0QQ6 trade ideas
Roche vs. Novo Nordisk: Who will suffer the Weight Loss?Roche (ticker: ROG.SW) is losing ground on the stock due to the side effects of its new weight loss pill, CT-996, which is still in the testing phase. After a rally that boosted its shares 40% between May and September, the Swiss drugmaker has seen an 11% drop in its shares in September alone, including a decline of up to 6.75% on the U.S. stock market.
The weight-loss drug market, driven by the success of Novo Nordisk's Ozempic (ticker: NVO), is projected to reach $130 billion annually by the end of the decade. However, Roche faces challenges following trials of CT-996, where five out of six patients suffered nausea and one in six had “chronic reflux,” which has affected its competitiveness. Despite these adverse results, Manu Chakravarthy, director of product development for Roche's cardiovascular, renal and metabolism division, believes the trials are still encouraging and plans to continue with larger clinical studies to determine tolerability and improve the drug's profile.
Comparing the two companies' charts, Roche showed significant progress versus Novo Nordisk through July 31. However, after a failed attempt to break above its highs on September 2, Roche is currently in a support zone, having broken downward from the bullish channel it had held since May. In contrast, Novo Nordisk lost positions from June 24 until August 7, at which point it began to recover towards the middle of its long-term range. Currently, Roche could pull back to 214 Swiss francs if its downtrend continues. On the other hand, Novo Nordisk remains in an intermediate trading zone around $134, with a possible uptrend in the short term.
Ion Jauregui - ActivTrades Analyst
*******************************************************************************************
The information provided does not constitute investment research. The material has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and such should be considered a marketing communication.
All information has been prepared by ActivTrades ("AT"). The information does not contain a record of AT's prices, or an offer of or solicitation for a transaction in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information.
Any material provided does not have regard to the specific investment objective and financial situation of any person who may receive it. Past performance is not reliable indicator of future performance. AT provides an execution-only service. Consequently, any person acing on the information provided does so at their own risk.
Roche Analysis 6/26DISCLOSURE: as of 6/26 I have no open position in SIX:RO
Roche is a Swiss based pharmaceutical conglomerate with a diverse range of operations and brands. The company has a long history of profitability and high returns on investment.
Management Effectiveness: Roche has been around since 1896 and has had consistent growth over the economic cycles. Return on equity has been averaging 40% and although margins have compressed in recent years the company remains highly profitable and in a stable leverage position.
Valuation: With a price to earnings of 20 and price to cash flow of 15 if looks potentially undervalued. I like companies that have a return on equity double that of the price to earnings, and that rule of thumb is met in this case.
Summary: Roche looks like a quality company to potentially take some profits and diversify from my NASDAQ:SIGA position. However, for now it will stay on the watch list. I will be looking at OANDA:USDCHF as well as the valuation metrics I mentioned above.
Here on my macroeconomic and current research shortlist watchlists:
www.tradingview.com
www.tradingview.com
Thanks for reading, have a good one
Roche: Ready for 120% Growth?We're trying something with Roche here, where we think that we are currently in Wave (5), having recently completed Wave (4). This assessment is better visualized on the daily chart. Hence, we should maintain the 61.8% level for this Wave 4. Anything below would statistically be too low, while above, we aim at least to revisit the old high, up to an Wave 5 extension. This scenario would place us at a level of $552, marking a 120% increase from our entry point, with a stop-loss set at 6.5%, resulting in a risk-to-reward ratio of 18.65%, which is phenomenal if it materializes. We believe the risk-reward ratio is so favorable that we must proceed with this trade. As long as we don't fall below the invalidation zone, i.e., the level of Wave (1), we continue to anticipate that Wave 4 holds. As mentioned, it wouldn't make sense for us to fall below the 61.8% level for Wave (4), as statistically, there's little to gain beyond that point.
Hold it like a rock - Roche, what an opportunity.Hi, 1PERCENT here.
Roche Holding, a Swiss multinational biopharma company. It is like the Apple of biopharma.
There were only 3 pull backs greater than 30% in the history of the stock.
2002 ~ 2003: -45.33%
2006 ~ 2011: -52.40%
2014 ~ 2018: -30.24%
2022 ~ present: -44.89%
It is at the support zone that initiated the +95% move up from 2018 to 2022, and also is testing the trendline connecting the lows in 2003 and 2011.
If you live in the US, you might want to have some exposure to Swiss assets (CHF or stocks) and Gold & silver.
The US dollar is losing value against the Swiss Francs in the long term.
Otherwise, Roche stock price must hold up at the current support zone , otherwise, we are open for a 30+% drop to the next support zone, which will be of course, an absolute bargain.
Also, it looks like the previous turnovers from the lows were always accompanied by the MA36 and MA12 crossing (MA12 over MA36)
However, we do not have it here yet. So, let's keep an eye on it.
That's it.
1PERCENT
ROG corrective rally to come?ROG has experienced a 5 wave decline visible on the weekly timeframe. We can now expect at least a 3 wave corrective rally that can potentially reach the golden pocket at $332
Roche HoldingsThis is one of those companies you can't afford not to look into. Roche is one of the world's largest biotech companies and a global leader in pharmaceuticals and diagnostics. This leading position translates to strong market share, revenue, and profitability. The company operates across various segments like oncology, immunology, neuroscience, and diagnostics, reducing dependence on any single market or product. This diversification provides stability and growth potential.
Roche boasts a strong balance sheet with low debt and substantial cash reserves, providing financial flexibility for future investments and growth initiatives. It has a track record of consistent dividend payments and increases, appealing to investors seeking income.
Strong fundamentals and attractive technicals have brought Roche to our attention. We are looking at entry when the market opens.
Long Term Weekly Trend holds for nowTrend started in 2012 held during the week. If the price accumulates at the current level and we breakout to the upside, I will watch the marked zones of interest and see how the price reacts.
If we breakout to the down side, I will look for interesting price levels and keep an eye on the trend established in 2003.
As of now I am long.
Roche Holding AG (ROG.SW) Stock Hello ladies and gentlemen,
according to my stock chart analysis, there is a high probability of a decline toward the $303.50 level in the next few days!
Roche Holding AG bullish scenario:The technical figure Triangle can be found in the daily chart in the German company F. Hoffmann-La Roche AG (ROG.vx). Roche is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. Roche is the fifth largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. The Triangle broke through the resistance line on 07/09/2022, if the price holds above this level, you can have a possible bullish price movement with a forecast for the next 10 days towards 333.65 CHF. Your stop-loss order, according to experts, should be placed at 311.75 CHF if you decide to enter this position.
Roche announced the launch of the Digital LightCycler System, Roche’s first digital polymerase chain reaction (PCR) system. This next-generation system detects disease and is designed to accurately quantify trace amounts of specific DNA and RNA targets not typically detectable by conventional PCR methods.
The Digital LightCycler System will allow clinical researchers to divide DNA and RNA from an already extracted clinical sample into as many as 100,000 microscopic individual reactions. The system can then perform PCR and produce highly sophisticated data analysis on the results.
Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
wedge, divergence and coming dividendsIt it a good idea to buy at the bottom of wedge right before the date of dividend pay? Probably we will have a chance ;-)
ROG Breakout. Broke its all time high.Good news combined with a perfect breakout at 357. Just needs a bit more volume.
Roche reversalRoche making higher lows inside a descending broadening wedgem, while showing signs of accumulation with a sell wall at 326.85$. The bullish engulfing candles on Jan 11 and the Marubozu on Feb 4 show that the demand for this asset is high at the previous Peak back in December 2014. The fact that there is also MACD hidden bullish divergence on the daily and the monthly strengthens the argument for a reversal and a break out of this structure in the coming weeks or months.
LONG ROGExpecting bounce from extremely oversold weekly and daily levels. If stop breached, be prepared to catch new daily reversal on lower levels with a tight stop.
Roche Holding - ROG AnalysisThe market is bullish and the idea is to invest in the Market direction.
Fundamental Analysis Info:
Britain is in talks with Swiss drugmaker Roche Holding AG (ROG.S) to buy an accurate COVID-19 antibody test, following the lead of the European Union and United States, which had already given preliminary approval to the tests.
RO Long : +% 2.53 - % 4.91Parameters :
Position Size : %1
Risk/Reward Ratio : 3
Stop-Loss : 275
Goal : 284.2
*** NOTE : If opens too high , Goal is 290.8.
Roche On stage With Mr Trump Bullish $rhhbyOn Friday, Swiss pharmaceutical company Roche (RHHBY) announced it received emergency approval from the U.S. Food and Drug Administration for the use of its new diagnostic test for Covid-19, the disease caused by the novel coronavirus that was first identified in China near the end of 2019.
More specifically, the test kit can be used to detect cells of the virus itself, which is classified as SARS-CoV-2, when samples are run through Roche's fully automated cobas 6800 and 8800 systems, which are already in frequent use throughout the world.
Source gurufocus
